Lupin & DKSH sign an exclusive licensing & supply agreement to market five biosimilar candidates in Philippines

New Delhi: Global pharma major, Lupin Limited and DKSH, a leading partner for healthcare companies, have signed an exclusive license and supply agreement to commercialize five of Alvotech’s proposed biosimilars in the Philippines.

The biosimilars planned under this agreement include biosimilar Prolia® (denosumab 60mg/ml), Xgeva® (denosumab 70 mg/ml), Simponi® (golimumab), and Eylea® (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.

According to the agreement, Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.

These reference products are used to treat disorders relating to bone disease, oncology, immunology and ophthalmology. This agreement enhances Multicare’s oncology, rheumatology, gastroenterology and ophthalmology, portfolio, which currently consists of three biosimilar candidates and over 50 generic medicines.

“We are pleased to announce the addition of five new biosimilar candidates to our portfolio, which will provide patients in Philippines with effective, high-quality and affordable treatment options,” said Gabriel Georgy, Regional Head Southeast Asia, Lupin.

Peter Dolinsky, Vice President Own Brands, Asia Pacific at DKSH added, “We are delighted to partner with Lupin and bring these important therapeutic offerings to patients in the Philippines. This partnership is in line with our purpose of enriching people’s lives, and we are proud to be working with a strong local partner to make this happen.”